Actively Recruiting
Evaluation of TQC2731 Injection Versus Placebo in Adults With Poorly Controlled Severe Asthma A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Updated on 2026-08-19
660
Participants Needed
101
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of TQC2731 injection in adults with severe asthma that is not adequately controlled. The study aims to compare TQC2731 with a placebo to better understand its impact on asthma exacerbations and other clinical outcomes in this population. Participants are randomly assigned in a 11 ratio to receive either TQC2731 injection or placebo via subcutaneous injection every 4 weeks. Treatment cycles last 4 weeks each, with study drug administration continuing from Day 0 up to Week 48. The trial includes two groups one receiving the active drug and the other receiving placebo, both with the same dosing schedule. During the study, participants will be monitored for asthma exacerbations, lung function through forced expiratory volume in 1 second FEV1, asthma control questionnaires, quality of life assessments, symptom diaries, and biomarker changes such as blood eosinophils and immunoglobulin E levels. Safety assessments include monitoring for anti-drug antibodies and neutralizing antibodies. The primary outcome is the annualized incidence of asthma exacerbations from the first day of dosing through 52 weeks. Secondary outcomes and safety follow-up extend up to Week 64.
CONDITIONS
Brief Title
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
Research Team
J
Jinping Zheng, Doctor
Q
Qingling Zhang, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here